MX2018014743A - Metodo para tratar fibrosis hepatica. - Google Patents
Metodo para tratar fibrosis hepatica.Info
- Publication number
- MX2018014743A MX2018014743A MX2018014743A MX2018014743A MX2018014743A MX 2018014743 A MX2018014743 A MX 2018014743A MX 2018014743 A MX2018014743 A MX 2018014743A MX 2018014743 A MX2018014743 A MX 2018014743A MX 2018014743 A MX2018014743 A MX 2018014743A
- Authority
- MX
- Mexico
- Prior art keywords
- liver fibrosis
- treating liver
- fibrosis
- treating
- t2dm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
Abstract
Se proporciona un método para tratar fibrosis hepática con antagonistas de CCR2. La fibrosis hepática puede estar asociada con esteatohepatitis no alcohólica (NASH), enfermedad de hígado graso no alcohólico (NAFLD), cirrosis emergente, fibrosis hepática no cirrótica, diabetes mellitus tipo 2 (T2DM) o síndrome metabólico (MS).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662345086P | 2016-06-03 | 2016-06-03 | |
PCT/US2017/035628 WO2017210526A1 (en) | 2016-06-03 | 2017-06-02 | Method of treating liver fibrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018014743A true MX2018014743A (es) | 2019-04-11 |
Family
ID=60479090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018014743A MX2018014743A (es) | 2016-06-03 | 2017-06-02 | Metodo para tratar fibrosis hepatica. |
Country Status (15)
Country | Link |
---|---|
US (3) | US10682344B2 (es) |
EP (1) | EP3463350B1 (es) |
JP (2) | JP2019517523A (es) |
KR (1) | KR102444366B1 (es) |
CN (2) | CN109475537A (es) |
AU (1) | AU2017274521B2 (es) |
BR (1) | BR112018074452A2 (es) |
CA (1) | CA3025671A1 (es) |
ES (1) | ES2966111T3 (es) |
IL (1) | IL263245B (es) |
MX (1) | MX2018014743A (es) |
RU (1) | RU2740902C2 (es) |
SG (2) | SG10202012080UA (es) |
WO (1) | WO2017210526A1 (es) |
ZA (1) | ZA201807992B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
US11571431B2 (en) | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
US10682344B2 (en) * | 2016-06-03 | 2020-06-16 | Chemocentryx, Inc. | Method of treating liver fibrosis |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
JP6678779B2 (ja) | 2016-06-13 | 2020-04-08 | ギリアード サイエンシーズ, インコーポレイテッド | Fxr(nr1h4)調節化合物 |
US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
CN110191724A (zh) * | 2016-11-10 | 2019-08-30 | 盖尔梅德研究与发展有限公司 | 纤维化的治疗 |
AU2018243719B2 (en) | 2017-03-28 | 2021-01-21 | Gilead Sciences, Inc. | Therapeutic combinations for treating liver diseases |
KR102600115B1 (ko) | 2017-06-05 | 2023-11-09 | 바이킹 테라퓨틱스 인코포레이티드 | 섬유증 치료를 위한 조성물 |
JP2020532551A (ja) | 2017-09-03 | 2020-11-12 | アンジオン バイオメディカ コーポレーション | Rho関連コイルドコイルキナーゼ(ROCK)阻害剤としてのビニルヘテロ環 |
JP7263659B2 (ja) | 2018-02-02 | 2023-04-25 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | カルボン酸基を含む窒素含有ベンゾ複素環化合物、その調製方法及び使用 |
US11964964B2 (en) * | 2018-06-12 | 2024-04-23 | Xizang Haisco Pharmaceutical Co., Ltd. | Thyroid hormone receptor agonists and uses thereof |
JP2022514731A (ja) * | 2018-08-14 | 2022-02-15 | アヴォリント | 原発性硬化性胆管炎の処置方法 |
JP2022510691A (ja) * | 2018-12-05 | 2022-01-27 | バイキング・セラピューティクス・インコーポレイテッド | 線維症及び炎症の処置のための組成物 |
AU2020209564B2 (en) | 2019-01-15 | 2022-12-01 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
CA3233305A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
WO2020181163A1 (en) * | 2019-03-06 | 2020-09-10 | Tobira Therapeutics, Inc. | Lipid-based formulation of cenicriviroc |
WO2020227549A1 (en) | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
MX2022000802A (es) * | 2019-07-30 | 2022-02-16 | Kobiolabs Inc | Kit para predecir o diagnosticar enfermedad de higado graso no alcoholico, y metodo para diagnosticar enfermedad de higado graso no alcoholico. |
CN114245743B (zh) * | 2019-07-30 | 2023-12-08 | Ko生物技术有限公司 | 预防、缓解或治疗肝损伤的组合物和方法 |
US20220387467A1 (en) * | 2019-11-22 | 2022-12-08 | Avolynt | Use of sglt2 inhibitors to treat primary billiary cholangitis |
CN116942684A (zh) * | 2020-02-20 | 2023-10-27 | 甘莱制药有限公司 | 一种用于治疗脂肪性肝炎的药物组合物及其制备方法 |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
KR102393676B1 (ko) * | 2020-10-08 | 2022-05-04 | 주식회사 큐롬바이오사이언스 | 베타-라파촌을 유효성분으로 포함하는 담즙 정체성 간질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1753758B1 (en) * | 2004-05-26 | 2009-03-11 | Janssen Pharmaceutica N.V. | Mercaptoimidazoles as ccr2 receptor antagonists |
JP5253815B2 (ja) | 2005-01-14 | 2013-07-31 | ケモセントリックス, インコーポレイテッド | ヘテロアリールスルホンアミドおよびccr2 |
US7622583B2 (en) * | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
US8067457B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
US20070219245A1 (en) | 2006-03-14 | 2007-09-20 | Cuifen Hou | Method of use for substituted dipiperidine ccr2 antagonists |
US8519135B2 (en) * | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
DE602007012261D1 (de) * | 2006-07-14 | 2011-03-10 | Chemocentryx Inc | Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose |
US7776877B2 (en) * | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
WO2009009740A1 (en) * | 2007-07-12 | 2009-01-15 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treament of inflammation |
PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
CN102239180B (zh) * | 2008-08-18 | 2014-12-31 | 辉瑞大药厂 | 抗ccr2抗体 |
PT3091012T (pt) * | 2009-12-17 | 2018-06-27 | Centrexion Therapeutics Corp | Antagonistas do receptor ccr2 e suas utilizações |
WO2012114223A1 (en) * | 2011-02-25 | 2012-08-30 | Pfizer Limited | A method of treating liver fibrosis |
US8658787B2 (en) * | 2011-09-16 | 2014-02-25 | Galectin Therapeutics Inc. | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
IN2014DN08582A (es) * | 2012-05-09 | 2015-05-22 | Boehringer Ingelheim Int | |
TWI696462B (zh) * | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
EP3191100A4 (en) * | 2014-09-12 | 2018-05-30 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
US10682344B2 (en) * | 2016-06-03 | 2020-06-16 | Chemocentryx, Inc. | Method of treating liver fibrosis |
-
2017
- 2017-06-02 US US15/612,124 patent/US10682344B2/en active Active
- 2017-06-02 CA CA3025671A patent/CA3025671A1/en active Pending
- 2017-06-02 SG SG10202012080UA patent/SG10202012080UA/en unknown
- 2017-06-02 RU RU2018145459A patent/RU2740902C2/ru active
- 2017-06-02 BR BR112018074452-2A patent/BR112018074452A2/pt unknown
- 2017-06-02 KR KR1020187037797A patent/KR102444366B1/ko active IP Right Grant
- 2017-06-02 MX MX2018014743A patent/MX2018014743A/es unknown
- 2017-06-02 WO PCT/US2017/035628 patent/WO2017210526A1/en unknown
- 2017-06-02 CN CN201780048523.5A patent/CN109475537A/zh active Pending
- 2017-06-02 AU AU2017274521A patent/AU2017274521B2/en active Active
- 2017-06-02 JP JP2018563453A patent/JP2019517523A/ja not_active Withdrawn
- 2017-06-02 EP EP17807548.7A patent/EP3463350B1/en active Active
- 2017-06-02 CN CN202210819034.8A patent/CN115154467A/zh active Pending
- 2017-06-02 ES ES17807548T patent/ES2966111T3/es active Active
- 2017-06-02 SG SG11201810602YA patent/SG11201810602YA/en unknown
-
2018
- 2018-11-25 IL IL263245A patent/IL263245B/en unknown
- 2018-11-26 ZA ZA2018/07992A patent/ZA201807992B/en unknown
-
2020
- 2020-05-06 US US16/867,956 patent/US11357760B2/en active Active
-
2022
- 2022-05-11 US US17/662,979 patent/US20220313668A1/en active Pending
- 2022-11-30 JP JP2022191906A patent/JP7431931B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
IL263245A (en) | 2018-12-31 |
CN109475537A (zh) | 2019-03-15 |
ES2966111T3 (es) | 2024-04-18 |
CA3025671A1 (en) | 2017-12-07 |
RU2018145459A3 (es) | 2020-07-09 |
IL263245B (en) | 2021-09-30 |
ZA201807992B (en) | 2023-10-25 |
EP3463350B1 (en) | 2023-09-13 |
WO2017210526A1 (en) | 2017-12-07 |
US20200268727A1 (en) | 2020-08-27 |
JP2023022227A (ja) | 2023-02-14 |
AU2017274521B2 (en) | 2021-08-19 |
KR102444366B1 (ko) | 2022-09-19 |
KR20190026687A (ko) | 2019-03-13 |
SG11201810602YA (en) | 2018-12-28 |
JP2019517523A (ja) | 2019-06-24 |
EP3463350A4 (en) | 2020-01-29 |
US11357760B2 (en) | 2022-06-14 |
CN115154467A (zh) | 2022-10-11 |
BR112018074452A2 (pt) | 2019-03-19 |
SG10202012080UA (en) | 2021-01-28 |
RU2740902C2 (ru) | 2021-01-21 |
US10682344B2 (en) | 2020-06-16 |
JP7431931B2 (ja) | 2024-02-15 |
US20220313668A1 (en) | 2022-10-06 |
AU2017274521A1 (en) | 2018-12-13 |
RU2018145459A (ru) | 2020-07-09 |
EP3463350A1 (en) | 2019-04-10 |
US20170348293A1 (en) | 2017-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201807992B (en) | Method of treating liver fibrosis | |
PH12020551025A1 (en) | Incretin analogs and uses thereof | |
PH12017502359A1 (en) | Glucagon and glp-1 co-agonist compounds | |
PH12020551024A1 (en) | Incretin analogs and uses thereof | |
MX360140B (es) | Biomarcadores de la enfermedad del higado graso no alcoholico (nafld) y la esteatohepatitis no alcoholica (nash) y usos de estos. | |
MX2019005533A (es) | Tratamiento de la fibrosis. | |
WO2018094265A3 (en) | Method of treating glycogen storage disease | |
MX2016010447A (es) | Composiciones y metodos para tratar diabetes y enfermedades hepáticas. | |
EP3787618A4 (en) | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | |
MX369571B (es) | Composicion para prevenir o tratar enfermedades del higado graso. | |
IL276935A (en) | A therapeutic agent for hepatocellular carcinoma | |
WO2020009740A3 (en) | Compositions and methods of use thereof for treatment of metabolic diseases and related disorders | |
AR104844A1 (es) | Método para recubrimiento de un chupetín | |
CY1124611T1 (el) | Θεραπειες μη-αλκοολικης στεατοηπατιτιδας (nash) | |
MX2019002579A (es) | Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado. | |
EA202091461A1 (ru) | Пептиды для лечения и профилактики неалкогольной жировой болезни печени и фиброза | |
Fortington et al. | Same, same but different… injury and safety promotion in rugby | |
苗露 et al. | The effect of CeO2 content on properties of steel 45 Ni-WC coating formed by vacuum fusion sintering | |
WO2020118199A3 (en) | Compositions and methods for treating or preventing nash, nafld, diabetes, atherosclerosis, and/or obesity | |
Tohkairin | Taxonomic and phylogeographic studies of Crystallichthys matsushimae (Pisces: Liparidae) | |
MATSUMIYA | Urbanization of Ulaanbaatar with reference to Ger Areas | |
Jiaxu | Influence of the Traditional Chinese Culture on the Expansion of Buddhism in China | |
TH176687S (th) | อาคารสำเร็จรูป | |
TH72696S1 (th) | อาคารสำเร็จรูป | |
TWD170224S (zh) | 門板(二) |